Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BICO Group AB Class B ( (SE:BICO) ).
BICO Group AB has appointed Maria Rankka as the new Board Chair, following the resignation of Rolf Classon due to health reasons. Rankka, an experienced investor and entrepreneur in Health Tech and Life Science, aims to focus on advancing BICO’s strategic goals and enhancing its market position. Her appointment is expected to strengthen BICO’s mission of supporting pharma and biopharma companies in accelerating innovations to market, contributing to healthier societies.
The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.
More about BICO Group AB Class B
BICO Group AB operates in the lab automation and life science solutions industry, providing selected workflows to the pharmaceutical and biotech sectors. With over 48,000 instruments installed globally, BICO’s products and software are utilized in more than 3,500 laboratories, including those of the world’s top 20 pharmaceutical companies. The company is listed on Mid-Cap, Nasdaq Stockholm under the ticker BICO.
Average Trading Volume: 294,015
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.5B
Find detailed analytics on BICO stock on TipRanks’ Stock Analysis page.